Twist Bioscience Corporation revised earnings guidance for the fiscal year 2024. For the full fiscal year 2024, total revenue is expected to be in the range of $300 million to $304 million compared to previous guidance of $288 million to $293 million, indicating year over year growth of 22% to 24%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
47.01 USD | +1.10% | +10.95% | +27.54% |
05-03 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
05-03 | Sector Update: Health Care Stocks Mixed in Afternoon Trading | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.54% | 2.71B | |
-2.32% | 92.59B | |
+3.68% | 41.43B | |
-10.90% | 33.49B | |
-19.56% | 14.62B | |
-9.06% | 12.77B | |
-11.34% | 11.58B | |
-43.53% | 11.35B | |
+3.75% | 8.97B | |
-6.32% | 8.3B |
- Stock Market
- Equities
- TWST Stock
- News Twist Bioscience Corporation
- Twist Bioscience Corporation Revises Earnings Guidance for the Fiscal Year 2024